Introduction Cyclosporine and methotrexate are the two preferred first-line immunosuppressive treatments in atopic
Introduction
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases in both children and adults with a prevalence of 10-20%. 1, 2 In most of cases, AD patients are mainly managed in primary care with the following treatment strategies: daily emollient application, use of anti-inflammatory topical therapy including topical steroids and topical calcineurin inhibitors and avoidance of individual triggering factors for mild AD, and conventional topical anti-inflammatory therapy with a proactive approach and phototherapy for moderate AD. In the more severe AD patients, that is patients with chronic active disease or subintrant flares with high impact on quality of life, immunosuppressive treatment is currently used.
The major therapeutic challenges in immunosuppressive treatment for chronic skin diseases are efficacy and safety in the long term. Furthermore, efficacy should optimally include persistent drug effect after its discontinuation. In a pragmatic approach to manage AD patients with chronic and severe disease, two questions can be raised as follows: 'how long can a patient remain on an immunosuppressive treatment in conditions that are both safe and efficient? (i.e. the time on drug)' and 'how long can a patient be free of immunosuppressive treatment after its discontinuation? (i.e. the time between two drugs)'. Drug survival analysis has recently been used to explore the first issue, but data on the second issue are lacking.
Cyclosporine (CYC) and methotrexate (MTX) are the two preferred first-line immunosuppressive treatments in moderateto-severe AD in France, probably with different treatment profiles in clinical practice. Only CYC is approved as the first-line immunosuppressive treatment for severe atopic dermatitis in France. But MTX is an off-label immunosuppressive treatment option for patients with severe atopic dermatitis. In clinical practice in France, cyclosporine and methotrexate are both the first-line immunosuppressive treatment of choice currently used for patients with atopic dermatitis requiring a first-line immunosuppressive. 3, 4 The objective of this work was to compare the treatment profiles of MTX and CYC as first-line immunosuppressive treatment in AD patients, using two survival analyses: 'drug survival' and 'postdrug survival' analyses.
Materials and methods

Study design and setting
This retrospective longitudinal study was performed among children and adult patients with moderate-to-severe atopic dermatitis treated with at least one immunosuppressive drug, either MTX or CYC, between January 2007 and December 2016, at three French dermatology departments (Rennes University Hospital, Saint-Brieuc Hospital and Le Mans Hospital).
Participants
All patients treated with MTX or CYC as first-line immunosuppressive treatment for AD were included for the survival analysis.
In a first step, electronic data were used to search for patients with moderate-to-severe AD: at Rennes University Hospital, patients were selected from the biomedical database of the hospital (eHOP) 5 by entering the terms: 'atopic dermatitis' or 'eczema' or 'atopic eczema' and 'MTX' or 'CYC'; at Saint-Brieuc and Le Mans Hospitals, patients were selected from the French hospital discharge database (PMSI, medicalized information system program), using the ICD-10 code L20 'atopic dermatitis'.
Patients with moderate-to-severe AD are usually hospitalized at least once to introduce the first-line immunosuppressive treatment at Saint-Brieuc and Le Mans Hospitals. In a second step, a total of 546 medical visit records of selected patients were read to check that MTX or CYC were given for AD at Rennes University Hospital and to select patients with MTX or CYC for AD at Saint-Brieuc and Le Mans hospitals. A total of 490 patients were excluded for the following reasons: CYC or MTX prescribed for other diseases at Rennes University Hospital (n = 274); no prescription of CYC or MTX for AD at Saint-Brieuc et Le Mans (n = 198); initiation of treatment before 2007 (n = 6); first-line systemic treatment of AD not CYC or MTX (n = 4); unknown date of initiation of CYC or MTX treatment (n = 2); and treatment duration with MTX or CYC under 2 months (n = 6).
Variables
A standardized questionnaire was used to collect the following information: gender; age at initiation of first-line of immunosuppressive treatment; weight; personal and familial history of atopy; previous treatments for AD (anti-inflammatory topical treatments, i.e. corticosteroids and calcineurin inhibitors, or phototherapy); age at AD onset; immunosuppressive treatments following first-line immunosuppressive treatment with MTX or CYC (i.e. mycophenolate mofetil, azathioprine, omalizumab, intravenous immunoglobulins and alitretinoin), starting dose, maximum dose during treatment, date of start and end of each treatment line and reason for discontinuation (controlled AD, primary or secondary failure, pregnancy, non-compliance and side-effects). We defined two categories of dosage for each treatment: for MTX: ≤15 mg weekly and >15 mg weekly; and for CYC: ≤3.5 mg/kg/day and >3.5 mg/kg/day. For children under 12 years, a high dose of MTW was defined as >0.25 mg/kg weekly. An interruption of treatment longer than 3 months was considered as a discontinuation of treatment. Adverse events were collected and classified as serious side-effects (death, hospitalization, disability, or life-threatening consequences) and other side-effects (separated into two categories of outcome: discontinuation of the treatment and continuation of treatment).
Drug survival analysis
Patients treated with MTX and CYC as first-line immunosuppressive treatment for AD were included in the 'drug survival' analysis. Survival analysis is a method for analysing data for the occurrence of an event. Drug survival is the time patients remain on MTX or CYC, and the event is the discontinuation of MTX or CYC. The event date considered was the date of discontinuation of treatment whatever the reason. Time data was censored when patients were lost to follow-up or were still being treated at the end of data lock. The probability of continuing the treatment with MTX or CYC was analysed using the Kaplan-Meier method. The possible determinants of 'drug survival' for firstline immunosuppressive treatments were studied as follows: gender, age at the initiation of first-line immunosuppressive treatment, treatment used, maximum dosage of MTX or CYC as defined below.
Postdrug survival analysis
Patients who discontinued MTX or CYC as first-line immunosuppressive treatment for AD were included in the 'postdrug survival' analysis. 'Postdrug survival' was defined as the time between the end of the first-line immunosuppressive treatment with MTX or CYC and the second-line immunosuppressive treatment (time between two drugs). The event date considered was the date of initiation of the second-line immunosuppressive treatment. Time was censored when patients were lost to followup or did not start a second-line immunosuppressive treatment at the end of data lock. The probability of starting second-line immunosuppressive treatment after the discontinuation of firstline immunosuppressive treatment was analysed using the Kaplan-Meier method. The possible determinants of 'postdrug survival' were studied as follows: age at onset of disease, gender, long duration of first-line treatment, treatment used, high dose of the first-line treatment and discontinuation of the first-line treatment because the disease was under control. 'Drug survival' and 'postdrug survival' are presented in Fig. 1 .
Statistical analyses
Drug survival was analysed using the Kaplan-Meier survival curves. Two survival curves were defined and analysed separately: the date of treatment discontinuation (providing 'drug survival') and the date of initiation of the second-line treatment after discontinuation of MTX or CYC (providing 'postdrug survival'). Differences in drug survival between the two groups were analysed using the log-rank test. A descriptive analysis of qualitative data was performed, calculating numbers and percentages for each category, while quantitative data were described by calculating means, minimum and maximum values. We performed Cox regression analysis to identify predictive determinants for 'drug survival' and 'postdrug survival'. The variables with a Pvalue < 0.2 in the univariate analysis were entered into the multivariate model. A P-value under 0.05 was considered significant. Analyses were stratified according to centre. The chi-squaredtest was used to compare the reasons for treatment discontinuation. Statistical analyses were performed with R software version 3.3.0.
The study was approved by Ethics Committee of Rennes University Hospital (n°17.32) and patients gave their signed informed consent for the anonymous use of their medical information in the context of a medical research, in accordance with the principles of the Helsinki Declaration.
Results
Patients and treatment characteristics
In all, 56 patients with moderate-to-severe AD treated with CYC or MTX as first-line immunosuppressive treatment were included between 2007 and 2016. The baseline characteristics of these patients are shown in Table 1 . The mean age of patients was 34 AE 15 years, and the gender ratio was 1:1. For 89% of patients, the onset of AD occurred during childhood. All patients received topical anti-inflammatory treatments including topical steroids and topical calcineurin inhibitors; 57% of the patients were treated with phototherapy. In addition, 62% of the patients had been hospitalized for AD, including nine patients for serious skin infections.
Among the 56 patients with moderate-to-severe AD treated with CYC or MTX as first-line immunosuppressive treatment, 25 patients (44.6%) received CYC and 31 patients (55.4%) received MTX. The mean starting dose was 2.2 AE 0.63 mg/kg daily for CYC (n = 24) and 11 AE 3.63 mg weekly for MTX (n = 30). The mean maximum dose during treatment was 3.6 AE 1.25 mg/kg daily for CYC (n = 22) and 16 AE 4.59 mg weekly for MTX (n = 28). The details are given in the Table S1 .
The Sankey diagram shows the different sequences of first, second, third and subsequent courses of immunosuppressive treatments for the 56 patients with moderate-to-severe AD treated with CYC or MTX as a first-line immunosuppressive treatment (Fig. 2) .
At the end of data collection, 18 patients treated with MTX and 20 patients treated with CYC had discontinued the first-line immunosuppressive treatment. The reasons for discontinuation of the first-line immunosuppressive treatments are presented in Table 2 . The causes of discontinuation were obtained for 17 Drug and postdrug survivals of treatments for AD patients receiving MTX and 14 patients receiving CYC. Ten patients (55%) treated with MTX and three patients (16%) treated with CYC discontinued the treatment for controlled disease. Four patients (22%) treated with MTX and six patients (31%) treated with CYC discontinued the treatment following either primary or secondary failure. Only three (16%) patients discontinued CYC because of side-effects (not serious) and no patient discontinued MTX because of side-effects. There was no difference between cyclosporine and methotrexate for the reasons of treatment discontinuation ('controlled disease' and other reasons) (P-value = 0.11).
Drug survival
Comparison of drug survival for MTX and CYC as first-line immunosuppressive treatments The comparison of drug survival between MTX and CYC using Kaplan-Meier curves is presented in Fig. 3 . The median drug survival for CYC and MTX as first-line treatment was 8 and 23 months, respectively (log-rank P < 0.0001). Six months after initiation of MTX, 93% of patients were still being treated versus 60% of patients on CYC. Twelve months after the initiation of MTX, 71% of patients were still being treated versus 38% of patients on CYC. Table 3 shows the determinants of drug survival for MTX and CYC as first-line immunosuppressive treatment according to univariate and multivariate Cox regression analyses. There was no association between drug survival for MTX or CYC and age at initiation of treatment, gender and a high doses of MTX or CYC. CYC was the only predictive factor for shorter drug survival in univariate and multivariate models (HR 7.44; 95% CI 1.97-28.13; P < 0.003).
Postdrug survival
Comparison of postdrug survival for MTX and CYC as first-line immunosuppressive treatments Thirty-eight patients discontinued the first-line immunosuppressive treatment (n = 18 for MTX; n = 20 for CYC). The median duration of 'postdrug survival' was 12 months for MTX and 2 months for CYC (log-rank Number at risk Drug: Methotrexate Cyclosporine Figure 3 Comparison of 'drug survival' for cyclosporine (CYC) and methotrexate (MTX) as first-line immunosuppressive treatment for atopic dermatitis. The probability of continuing the first-line immunosuppressive treatment was analysed using the KaplanMeier method. P = 0.014) (Fig. 4) . Six months after discontinuation of MTX, 28% of the patients required a second-line treatment, whereas 75% required it after discontinuation of CYC. Six months after discontinuation because of disease control (n = 10 for MTX and n = 5 for CYC), no patient required second-line treatment after first-line immunosuppressive treatment with MTX versus 75% of patients after first-line treatment with CYC (log-rank P = 0.5). Six months after discontinuation for other reasons (n = 8 for MTX and n = 15 for CYC), 50% of the patients required second-line treatment after first-line immunosuppressive treatment with MTX versus 80% of patients after CYC (log-rank P = 0.13). Table 4 shows the determinants of 'postdrug survival' in univariate and multivariate Cox regression analyses. A long duration of the first-line treatment (HR = 1.13; IC95% (0.46-2.76); P = 0.79) and discontinuation of the first-line immunosuppressive treatment following disease control (HR = 0.76; IC95% (0.26-2.19); P = 0.60) were not associated with a shorter time between two drugs ('postdrug survival'). CYC was the only predictive factor for shorter 'postdrug survival' (HR = 3.00; IC95% (0.83-10.89); P = 0.09).
Discussion
This is the first direct comparison in daily practice between MTX and CYC in moderate-to-severe AD as first-line immunosuppressive treatments. Further to this, we were able to describe two treatment profiles using an approach based on 'drug survival' (time on drug) and 'postdrug survival' (time between two drugs). 'Drug survival' was significantly longer for MTX (median = 23 months) than for CYC (median = 8 months) and 'postdrug survival' was also significantly longer for MTX (median = 12 months) than for CYC (median = 2 months).
Comparative studies between two common systemic treatments in AD are a major research priority and a concern for clinicians, 6 as highlighted by a recent systematic review. 7 A recently published phase 3 randomized non-inferiority study comparing MTX at 15 mg weekly and CYC at 2.5 mg/kg/day showed a rapid onset of CYC efficacy with a larger proportion of patients achieving SCORAD 50 at 8 weeks (42% vs. 8%).
Increasing the dose of MTX to 25 mg weekly resulted in a similar clinical improvement to that obtained with high doses of CYC of 5 mg/kg/day at week 20. 8 A paediatric study of forty children suggested similar treatment responses between CYC ‡Defined as a duration of treatment >12 months for MTX and >6 months for CYC. §Defined as a mean maximum dose over treatment with CYC > 3.5 mg/kg daily, MTX > 15 mg weekly and for children under 12 years old, MTX > 0.25 mg/ kg weekly. Analysis stratified according to centre. Data are given as hazard ratios (HR) (95% confidence interval).
and MTX. 9 There is at present one multicentric randomized controlled trial in the United Kingdom comparing MTX and CYC among children with moderate-to-severe AD.
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The efficacy and safety results of these clinical trials are difficult to generalize to patients in daily practice settings because of strict inclusion criteria. Clinical studies often include betterfitted and more compliant patients. The severity profile of patients in trials is also different and does not reflect indications for treatment in daily clinical practice. For instance, Goujon et al. study included a severe profile of patients (80% of patients with baseline SCORAD index > 40), resulting in early treatment discontinuations. Retrospective studies in real-life settings in AD are complementary to clinical studies, providing additional information such as duration of treatment, the hierarchy of common treatments used in clinical practice and the prevalence of side events in 'real-world' patients with more comorbidities than in clinical trials. Few studies have been conducted in AD. 11, 12 Knowledge in these fields can be helpful in clinical decision-making in addition to clinical trials. The present study gives objective information about the time on MTX and CYC, which are both immunosuppressive treatments commonly used in daily practice for the treatment of moderate-to-severe AD. The comparison for 'drug survival' and 'postdrug survival' evidences significant differences between MTX and CYC in AD, suggesting their different treatment profiles. Unlike studies on efficacy, disease activity scores are not widely used in daily practice for the assessment of AD disease. Drug survival analysis, which concerns time on treatment, is an objective and informative outcome, especially for retrospective studies. Events that lead to withdrawal of a treatment are also informative, such as effectiveness, failure and side events. Therefore, drug survival analysis is increasingly used to assess longterm and chronic treatments such as biotherapies in rheumatology and dermatology. 13, 14 Long drug survival is assumed to attest of an adequate balance between efficacy and safety for both clinicians and patients. Drug survival analysis is also useful to identify predictive factors for long duration of treatment. It can also be of interest to analyse the time patients remain without treatment until a subsequent line of immunosuppressive treatment is required in chronic diseases. Indeed, treatment discontinuation often occurs in chronic skin diseases without the need for a switch of treatment, especially in AD. 'Postdrug survival' is a new approach that includes both the benefit of the first-line immunosuppressive treatment and the time free from any immunosuppressive treatment, which is a main concern for patients.
Some limitations to this study should be discussed. It is a retrospective study with a small sample size. It is also limited by some missing data concerning the causes of treatment discontinuation. Retrospective screening in medical records implies an information bias, but a uniform and extensive search was performed to minimize it.
The median 'drug survival' of 8 months for CYC reported here is consistent with two recent drug survival studies. 15, 16 In contrast, the median 'drug survival' for MTX is estimated at 23 months in this study, more than twice a previous result.
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The drug survival for MTX is significantly longer than for CYC. This finding could be explained by a particular immumodulatory effect of MTX, a use of MTX for less severe AD or a different safety profile between MTX and CYC. MTX discontinuation because of side events was not reported in this study. The shorter time on the drug for CYC could suggest rapid efficacy on AD. However, long-term CYC use is restricted by safety concerns, including potential nephrotoxicity and risk of skin cancer, with a treatment duration usually between 9 and 12 months. 18, 19 'Drug survival' can be influenced by various factors: the physician's prescribing behaviours, patient satisfaction, comorbidities, safety profile of the treatment, effectiveness and availability of alternative treatments. 13 As regards the causes of MTX and CYC discontinuation, the proportion of discontinuations for 'disease under control' among patients treated with CYC is lower in the present study than in others (16% vs. 22% and 45%) 15, 16 while the proportion of discontinuations for 'disease under control' for patients with MTX is in line with previous findings (55% vs. 49%). 17 This could suggest a higher severity profiles among patients treated with CYC in our population. The interpretation of the result is limited by the small number of reasons for discontinuation of the first-line treatment. 'Postdrug survival', which relates to the probability of starting a second line of treatment after withdrawal of a first treatment, has not been studied in AD, and is a major concern for physicians and patients. The result evidencing a shorter 'postdrug survival' for CYC (median = 2 months) than for MTX (median = 12 months) could suggest a suspensive effect of CYC without a maintenance effect in the long-term, a more severe disease profile in patients treated with CYC, or treatment discontinuation because of a serious side-effect. 'Postdrug survival' can be influenced by a remanence effect of the first-line treatment, by patient or physician decision to start a subsequent treatment, by duration and dosage of the previous treatment or by the availability of efficient alternative treatments. 'Postdrug survival' could reflect 'time to relapse' which has already been studied in studies on CYC in AD. 20, 21 However, the definition of 'relapse' mainly depends on the measurement of disease activity, which is often difficult to obtain in retrospective studies, whereas 'postdrug survival' is easily measurable and remains an objective outcome.
The differences in drug survival and postdrug survival between CYC and MTX point to two treatment profiles: on the one hand, the effect of MTX tends to correspond to immunomodulatory treatment, compared to CYC where the effect is more suspensive. Managing severe AD requiring immunosuppressive treatments is difficult. Recent guidelines have proposed a strategy to help the physician's clinical decision to initiate an immunosuppressive treatment for chronic and refractory AD. 22 However, no recommendation on the withdrawal of an immunosuppressive treatment in AD is provided. Indeed, the assessment of this disease is complex: clinical skin scores are used in clinical trials but are too time-consuming for the physicians in clinical practice, and they are static measurements of severity not taking account of the overall course of AD, with flares and sometimes spontaneous remissions. Drug survival studies are expanding in the field of management of chronic disease. We suggest including 'postdrug survival' for the purpose of better assessment in the use of immunosuppressive treatments, particularly in chronic skin diseases. Taking account both approaches, 'drug survival' and 'postdrug survival', our findings suggest that MTX may present a better treatment profile for the long-term control of moderate-to-severe AD, which is a well-identified challenge for clinical research and care. 23 This is the first direct comparison of MTX and CYC in moderate-to-severe AD in daily practice using 'drug survival', and a new concept of 'postdrug survival'. Two treatment profiles have been identified as follows: treatment duration of MTX is longer than that of CYC and the time to initiation of a new treatment is also longer after MTX withdrawal. 'Postdrug survival' could be a new tool for better assessment of the maintenance effect after immunosuppressive treatment discontinuation in chronic skin disease.
